Buy me a cup of tea or two? Change the number below to increment. i.e insert 2 = £8, 3 = £12, etc
Overheads to run this site, e.g. software packages, domain registration fees, software tools, misc items. Donate £4 or more so I have the fuel to keep on providing great content!
£4.00
Continuing with the output of updated clinical guidelines from ENETS, this paper is unlike the others so far in 2022/23/24 where the guidelines were set against several clinical questons for particular scenarios (presumably common in the NET patient population). So far,the clinical guidelines have centred on Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs) (Neuroendocrine Carcinoma (NEC) and Neuroendocrine Tumours (NET)).
The latest output comes in a different format than the GEP NEN output but is based on Lung NETs, i.e. well differeniated Lung NETs. I’m hoping it is a precurser to a set of updated Lung NEN guidelines. Although, as you will see there is no well differentiated grade 3 but a special category of well differentiated Lung NET with aggressive features. The Lung WHO 2021 classification of tumours (see Spotlight on Lung NENs) covered this special category (putting it into the large cell Lung NEC category as a placeholder). The same reference also failed to remove the ‘carcinoid‘ misnomer word, so my apologies for the use of this term in the attached reference link and in this post. However, still good to see output for Lung NETs. Worth pointing out that many Lung NEC are handled by Lung Multidiscplinary Teams (MDT), a slightly controversial point, particularly when the statistics for these Neuroendocrine Carcinomas (particulary small cell lung cancer (SCLC) are not inlcuded in overall NEN statistical data.
The format is based on a survey completed by thirty-four experts from 20 centres specialising in lung NET (I will in due course update my ‘Find a NET expert‘ section to incorporate this useful data).
Q1 and Q2 collected information about the medical specialist responding to the survey, who is the first point of contact for the patient, and the structure of the centre (type of structure, lung NET dedicated MDTB, number of lung NET dealing per year, and number of new lung NET dealing per year; details are shown in Table 1). |
Q3 and Q4 focused on the diagnostic investigations for specific clinical cases with potentially resectable disease (a peripheral or a centrally located lung NET lesion). |
Clinical case scenarios (Q5–11). |
Adjuvant treatment (Q12–15) |
Feasibility of conducting an adjuvant clinical trial (Q16–17) |
Follow-up protocols (Q18–20) |
Clinical cases (21, 22) |
Now read the reference material belowif you are interested in the output from this survey and the summarising information.
Click on the blue link below see read the discussion and the recommendations for each of those questions.
Anna Koumarianou, Pier Luigi Filosso, Lisa Bodei, Justo P. Castano, Lynnette Fernandez-Cuesta, Christophe M. Deroose, Matthieu Foll, Clarisse Dromain, Nicholas Simon Reed, Martyn Caplin, Jaume Capdevila, Jenny Falkerby, Antongiulio Faggiano, Andrea Frilling, Enrique Grande, Rodney J. Hicks, Atsuko Kasajima, Beata Kos-Kudla, B. A. Krishna, Eric Lim, Anja Rinke, Simron Singh, Chrissie Thirlwell, Marco Volante, Thomas Walter
I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.
Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional. Some content may be generated by AI which can sometimes be misinterpreted. Please check any references attached.
Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.
Thanks for reading.
Blog Facebook. Like this page please.
Personal Facebook. Like this page please.
Awareness Facebook Like this page please.
Follow me on X (formerly twitter)
Check out my online presentations
Check out my WEGO Health Awards
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumours and Other Somatostatin Receptor 2-Expressing Tumours Read the
Here is the monthly summary of December 2025 on RonnyAllan.NET – Every share helps someone understand or even work towards a diagnosis, discovery of the
Summary of 2025 from Ronny It was a good year for my advocacy work but a difficult year personally which had some impact on my
15 Christmas celebrations since diagnosis. A thankful statement My Facebook memories today are full of Christmas activities including my first Christmas following diagnosis of advanced
A Global first for NET. Omni 128cm Total Body PET at the Peter MacCallum Cancer Centre in Melbourne Australia. According to Professor Michael Hofman, they
My diagnosis came with many strange words including, “carcinoid” and “neuroendocrine” ……… can you spell that please, I said to the doctor. I had a
Ronny Allan’s ‘PoNETry’ © series can be shared with poetry credit to: RonnyAllan.NET Thanks for reading Ronny I also have one about Lanreotide (or “butt
When I was diagnosed, I didn’t even feel ill. It was therefore a bit of a shock being told I had metastatic cancer, advanced enough to
I was assessing performance of the awareness period in November 2025 on Facebook and was astonished to find the size of my reach on that
Subscribe to get the latest posts sent to your email.
